LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
LDE225 is a new medicine that blocks the Hedgehog (Hh) pathway. The Hh pathway is a cascade
of molecular events that control cell growth and have been linked with the development of
many human cancers, including pancreatic cancer. Information from research studies suggests
that LDE225 in combination with FOLFIRINOX may help to stop the growth of cancer cells. In
this research study, the investigators are looking to determine the maximum dose of LDE225 in
combination that can be given safely to patients with locally advanced or metastatic
pancreatic cancer.